New diabetes drug shows promise in chinese trial
NCT ID NCT02916706
First seen Jan 09, 2026 · Last updated Jun 22, 2026 · Updated 22 times
Summary
This study tested a drug called teneligliptin in 254 Chinese adults with type 2 diabetes. Half received the drug and half received a placebo for 24 weeks. The main goal was to see if teneligliptin lowers blood sugar levels (HbA1c) better than a placebo. Researchers also checked fasting blood sugar and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Investigational center
Beijing, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Teneligliptin
What this could lead to
If successful, this could provide a new oral medication option to help control blood sugar in people with type 2 diabetes.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all populations. Teneligliptin is already approved in some countries, so the benefit here is confirmatory rather than groundbreaking.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.